GC Pharma announced Wednesday that it has submitted an application for item permission for an anthrax vaccine, GC1109, co-developed with the Korea Disease Control and Prevention Agency (KDCA), to the Ministry of Food and Drug Safety (MFDS).GC1109 uses gene recombination technology to create the Prot
Dong-A ST announced Tuesday in a public filing that its operating profit for the third quarter decreased 7.7 percent year-on-year to 13.1 billion won. Revenue for the third quarter was 15.2 billion won, down 5.1 percent from 15.83 billion won in the same period of the previous year, and net income w
Prostate cancer drug Xtandi (enzalutamide), in combination with androgen deprivation therapy (ADT) to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC), will see its reimbursement status change from selective to essential starting next month.After winning approval for treating
Merck Life Science said it signed a memorandum of understanding (MOU) with Daewoong Pharmaceutical to enhance AI-based new drug development.The strategic partnership aims to apply AI in the entire lifecycle of drug development.Under the accord, Daewoong will employ Merck's products to identify, vali
KL& Partners, a Korean private equity firm, is in advanced talks to acquire Boryung Biopharma for an undisclosed sum.If the deal is finalized, it will mark approximately nine months since Boryung Biopharma was first put up for sale in February.According to industry sources, KL& Partners Consortium w
Samil Pharmaceutical announced Monday that it has signed an MOU with Aptar Pharma, a multinational company headquartered in the U.S., to secure competitiveness in the global eye drops business. The MOU was signed at the Convention on Pharmaceutical Ingredients (CPHI) 2023 last week in Barcelona, Spa
When treating rheumatoid arthritis, establishing insurance coverage guidelines regarding transitions between Janus kinase (JAK) inhibitors is urgently needed, a local rheumatology expert said. Professor Lee Sang-heon of the Rheumatology Department at Konkuk University Hospital spoke on the latest tr
Yuhan Corp. has recently revealed the success of the MARIPOSA clinical trial for Leclaza, its third-generation EGFR tyrosine kinase inhibitor (TKI). This development has sparked interest in whether it will mark the first global introduction of a homegrown anticancer drug.Professor Cho Byoung-chul, h
Barcelona, Spain -- A Korean company received high interest from overseas buyers at the world's largest pharmaceutical and biotechnology fair, CPHI Worldwide 2023, held in Barcelona, Spain, from Tuesday to Thursday.Alteogen, which has recombinant hyaluronidase (ALT-B4) technology, is the company. It
BARCELONA, Spain -- Daewoong Pharmaceutical, which participated in the world's largest pharmaceutical and bio exhibition, CPHI Worldwide 2023, showed confidence in the export competitiveness of homegrown P-CAB medications.In the CPHI 2023, held in Barcelona, Spain, from Tuesday to Thursday, Daewoong
Innovative medical technologies, such as digital treatment devices and diagnostic aids using artificial intelligence, have been decided to receive insurance benefits.The Ministry of Health and Welfare deliberated and approved the “Plan for Medical Benefits for Digital Therapeutic Devices and AI Inno
ICURE, a Korean biopharmaceutical company, has signed an export agreement with ANDK, a U.K.-based pharmaceutical trading company, to supply local anesthetics Plaster and Cataplasma in the Middle East and North Africa (MENA) region, including Kuwait, the UAE, and Egypt.ICURE specializes in the develo
SGLT2 inhibitor Jardiance (empagliflozin) has become a triple-crown treatment option in Korea, adding chronic kidney disease to its existing list of indications of type 2 diabetes and chronic heart failure, following Forxiga (dapagliflozin).Last Thursday, the Ministry of Food and Drug Safety (MFDS)
BARCELONA, Spain -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- "With the completion of the 33,000-square meter Innovative Discovery Center (IDC) in Busan in the first half of next year, we will further accelerate the R&D of new drugs and new biotechnologies through open innovation."On
In a strategic pivot, Medytox has altered its primary botulinum toxin (BTX) product to enter the Chinese market.According to the company, it recently decided to withdraw its drug registration application for Meditoxin (export name: Neuronox) with China's National Medical Products Administration (NMP
NKMAX, a Korean natural killer (NK) cell-based immunotherapy company, announced on Wednesday that its U.S. subsidiary, NKGen Biotech, has received U.S. FDA approval to initiate phase 1/2a clinical trials for SNK01, an NK cell therapy for Alzheimer’s disease in the U.S.Building on the results of the
The Ministry of Food and Drug Safety said it imposed an administrative penalty equivalent to a one-month suspension of clinical trials on Sanofi Pasteur Korea for the violation of labeling requirements in their ongoing meningococcal conjugate vaccine study.As a result of the violation of the Pharmac
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- A Korean company was honored with the title of "Best Poster" at the European Society for Medical Oncology Annual Meeting (ESMO 2023), the largest cancer society in Europe and one of the top three cancer societies in the world.Curoce
BARCELONA, Spain -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- CPHI Worldwide 2023 kicked off for a three-day run at the Fira Barcelona Gran Via convention center in Barcelona, Spain, on Tuesday.CPHI (Convention on Pharmaceutical Ingredients) is the world's largest pharma and bio exhi
JW Pharmaceutical, a Korean pharmaceutical company, said on Wednesday it signed a research agreement with Theraject Asia, a microneedle R&D company, to develop a microneedle-based hair loss treatment.Under the agreement, JW Pharmaceutical's Drug Research Center will utilize Theraject Asia's advanced